HR Execs on the Move

Central Wyoming Counseling Center

www.cwcc.us

 
Central Wyoming Counseling Center is a non-profit Community Mental Health and Substance Abuse Treatment Center that is dedicated to helping Residents of Wyoming.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.cwcc.us
  • 1430, Wilkins Circle
    Casper, WY USA 82601
  • Phone: 307.237.9583

Executives

Name Title Contact Details
Krista Campbell
Chief Financial Officer Profile

Similar Companies

Family Discount Pharmacy

Family Discount Pharmacy is a Carmichael, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hoodia Products

Hoodia Products is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sumitomo Pharma Co.,

Sumitomo Pharma is a pharmaceutical company that develops innovative pharmaceuticals and healthcare solutions for the betterment of healthcare and fuller lives of people worldwide.

CSI TESTING

CSI TESTING is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.